Revista Cubana de Medicina
versão On-line ISSN 1561-302X
VILAR GOMEZ, Eduardo et al. Prolonged treatment with alpha-2b interferon plus lamivudine in patients with e antigen positive chronic hepatitis B. Rev cubana med [online]. 2007, vol.46, n.4, pp. 0-0. ISSN 1561-302X.
The seroconversion rates of e antigen attained with the current antivirals do not exceed 35 %. The combination of immunomodulator and antiviral has been theoretically the most accepted strategy in the last five years; however, the results in clinical practice have been contradictory. This paper is aimed at evaluating the efficacy and security of a treatment scheme prolonged for 52 weeks with alpha-2b interferon plus lamivudine in patients with e antigen positive chronic hepatitis B. 46 patients selected at random were studied: 23 received 150 mg of lamivudine daily during 4 weeks, lamivudine plus alpha-2b (10 MU every other day) for 24 weeks, followed by lamivudine in the same dose and frequency until completing the 52 weeks. Other 23 were administered 150 mg of lamivudine daily for 4 weeks plus alpha 2b interferon (5 MU every other day) during 52 weeks. It was found that the antigen seroconversion rates were similar in both groups. A marked proportion of patients with combined prolonged treatment proved to be negative to the viral DNA (52 % vs. 26p = 0.06) and the surface antigen (48 % vs. 26 %, p = 0.11) compared with the controls. The improvement in the histological activity rate was observed in 48 % of the patients treated with combined prolonged treatment against 22 % of the controls (p = 0.06) It was concluded that the prolonged treatment of interferon and lamivudine during 52 weeks may have clinical benefits on the rates of sustained viral DNA loss, surface antigen and the histological activity index.
Palavras-chave : E antigen positive chronic hepatitis B; lamivudine; interferon; combined treatment.